Roberto Mitsui Akagi, MD
Endocrinology, Diabetes & Metabolism · Ashland, KYNPI 1992150403
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 187 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 18.9% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in KY, where the typical reported total is $3,450.
Across 187 payments — averaging $15.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$563
- Novo Nordisk$427
- Lilly USA, LLC$373
- Insulet Corporation$338
- Dexcom, Inc.$197
- Medtronic$172
- plus $903 from 12 others
What the payments were for
- Food & beverage$2,963100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 39 | $563 |
| Novo Nordisk | 28 | $427 |
| Lilly USA, LLC | 23 | $373 |
| Insulet Corporation | 26 | $338 |
| Dexcom, Inc. | 10 | $197 |
| Medtronic | 8 | $172 |
| Abbott | 10 | $165 |
| Tandem Diabetes Care, Inc. | 8 | $144 |
| Mannkind Corporation | 6 | $126 |
| Merck | 7 | $104 |
| AstraZeneca | 7 | $95 |
| BETA Bionics, Inc. | 4 | $86 |
| Amneal Pharmaceuticals LLC | 4 | $71 |
| AbbVie | 3 | $45 |
| Ascendis Pharma Endocrinology Inc | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Bayer | 1 | $14 |
How this compares
$2,974 in reported general payments places this provider in the 40th percentile of 90 endocrinology, diabetes & metabolism providers in Kentucky.
See all endocrinology, diabetes & metabolism providers in Kentucky →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 370 | $474,296 |
| TrulicityDulaglutide | 180 | $231,957 |
| MounjaroTirzepatide | 170 | $206,328 |
| Tresiba Flextouch U-200Insulin Degludec | 62 | $115,083 |
| JardianceEmpagliflozin | 74 | $91,091 |
| Humalog Kwikpen U-200Insulin Lispro | 46 | $82,358 |
| JanuviaSitagliptin Phosphate | 67 | $76,524 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 370 | $62,473 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 22 | $61,577 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 142 | $51,074 |
| ForteoTeriparatide | 12 | $50,623 |
| Novolog FlexpenInsulin Aspart | 122 | $45,303 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 76 | $38,007 |
| Humalog Kwikpen U-100Insulin Lispro | 109 | $33,206 |
| FarxigaDapagliflozin Propanediol | 40 | $31,274 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Forteo, Humalog | $373 | $493,178377 claims |
| Novo NordiskOzempic, Novolog, Levemir | $427 | $483,507399 claims |
| Boehringer IngelheimJardiance, Tradjenta | $563 | $112,875111 claims |
| MerckJanuvia | $104 | $76,52467 claims |
| AstraZenecaFarxiga | $95 | $31,27440 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Admelog | $18 | $23,75330 claims |
| AbbVieSynthroid | $45 | $4,70155 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $71 | $4,640545 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 90 endocrinology, diabetes & metabolism providers in Kentucky.
Other endocrinology, diabetes & metabolism in Ashland
- Moussa AlhajAshland$111K
- George BorstAshland$8K
- Hazel YangAshland$7K
- Bradley EilermanFlorence$1.3M
- Sergio Chang FigueroaMadisonville$1.2M
- Hisham AlrefaiLouisville$720K
- Harold BaysLouisville$214K
- Jahangir CyrusLouisville$155K
- Yancey HolmesCovington$148K
- Mehdi PoorkayLouisville$81K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.